McCarthy CP, Ballantyne CM, Blankstein R, Budoff MJ, et al. Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J 2025;290:325-338.
PMID: 40683616